Soleno Therapeutics logo
Soleno Therapeutics SLNO
report update icon

Quarterly report 2026-Q1
added 05-07-2026

Soleno Therapeutics Financial Statements 2025-2011 | SLNO

Annual Financial Statements Soleno Therapeutics

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

2.08 B 1.96 B 803 M 17.4 M 1.89 M 156 M 110 M 36.1 M 15.6 M 13.1 M 12.6 M 1.69 M - - -

Shares

50.8 M 40.2 M 16.5 M 8.4 M 5.32 M 79.6 M 34.1 M 21 M 8.98 M 3.1 M 1.89 M 254 K - - -

Historical Prices

41 48.7 48.7 2.07 0.355 1.96 3.46 1.77 1.77 4.25 6.7 6.65 - - -

Net Income

20.9 M -176 M -39 M -24.1 M -30.9 M -24.6 M -30.8 M -13.3 M -15.7 M -12.1 M -15.9 M -13.9 M -3.71 M -6.48 M -

Revenue

190 M - - - - - - - - 1.45 M 388 K - 3 M - -

Cost of Revenue

2.7 M - - - - - - - - 1.51 M 353 K - - - -

Gross Profit

- - - - - - - - - -58.5 K 34.9 K - 3 M - -

Operating Income

9.41 M -188 M -41.4 M -24.4 M -31.5 M -36.3 M -23.5 M -14.3 M -12.2 M -8.32 M -12.2 M -5.16 M -847 K - -

Interest Expense

- - 2.58 M 300 K 110 K 13 K 154 K 104 K -590 K 1.59 M - 4.13 M 2.86 M - -

EBITDA

11.4 M -186 M -39.4 M -22.4 M -29.6 M -30 M -21.2 M -11.8 M -8.07 M -13.5 M -12.1 M -5.13 M -805 K -3.57 M -

Operating Expenses

181 M 188 M 41.4 M 24.4 M 31.5 M 31.9 M 23.2 M 13.7 M 9.68 M 13.6 M 12.2 M 5.16 M 3.85 M - -

General and Administrative Expenses

132 M 106 M 13.5 M 9.84 M 10.8 M 8.76 M 6.93 M 6.56 M 6.58 M 6.74 M 6.14 M 2.67 M 1.47 M 1.13 M -

All numbers in USD currency

Quarterly Income Statement Soleno Therapeutics

2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

52.1 M 53.3 M 50.5 M 46.2 M 45.7 M 41.9 M 38.6 M 36.2 M 31.7 M 11.4 M 10.4 M 9.45 M 8.16 M 8.09 M 9.34 M 5.33 M 5.32 M 5.32 M 79.7 M 79.7 M 79.6 M 79.6 M 46.2 M 44.7 M 44.7 M 31.8 M 31.8 M 31.8 M 31.8 M 21.4 M 20.3 M 19.5 M 19.2 M 9.67 M 9.52 M 5.09 M 3.36 M 3.15 M 15.5 M 14.8 B 14 M 10 M 7.52 M 6.97 M 6.77 M 536 K 536 K 536 K 536 K 536 K - - - - - - - - - -

Net Income

31.4 M 26 M -4.71 M -43.8 M - -76.6 M -21.9 M -21.4 M - -10.9 M -8.48 M -8.36 M - -6.13 M -6.72 M -5.72 M - -8.14 M -11 M -8.95 M - -8.54 M -7.38 M -5.86 M - 889 K -10 M -7.03 M - -2.74 M -7.06 M -3.8 M - -3.79 M -3.97 M -2.89 M - -2.75 M -3.51 M -3.19 M - -3.29 M 1.88 M -11.7 M - -13.2 M -13.2 M -13.2 M - -1.59 M - - - - - - - - - -

Revenue

94.6 M 66 M 32.7 M - - - - - - - - - - - - - - - - - - - - - - -478 K -355 K -190 K - - - - - - 1 K 265 K - 329 K 2 K 447 K - 247 K 97 K 22 K - - - - - 3 M - - - - - - - - - -

Cost of Revenue

1.2 M 1.14 M 696 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 42 K 209 K - 399 K 51 K 461 K - 56 K 22 K 18 K - - - - - - - - - - - - - - - -

Gross Profit

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -41 K 56 K - -70 K -49 K -14 K - 191 K 75 K 4 K - - - - - - - - - - - - - - - -

Operating Income

31.3 M 22.1 M -6.52 M -45.7 M - -80.2 M -24.9 M -23.5 M - -10.4 M -8.62 M -8.47 M - -6.24 M -6.78 M -5.77 M - -8.29 M -11.1 M -9.16 M - -7.86 M -11.2 M -9.28 M - -6.13 M -5.62 M -4.98 M - -3.88 M -3.41 M -3.48 M - -2.63 M -2.97 M -1.37 M - -1.97 M -2.3 M -4.26 M - -3.18 M -3.04 M -2.43 M - -1.32 M -1.31 M -684 K - -993 K - - - - - - - - - -

Interest Expense

- - - - - - - - - - 147 K 113 K - 101 K 52 K 22 K - 34 K 41 K 1 K - 1 K 1 K 11 K - 29 K 47 K 57 K - 26 K 30 K 19 K - 3 K -88 K -672 K - - - - - - - 1 K - 752 K 670 K 388 K - 571 K - - - - - - - - - -

EBITDA

31.8 M 22.6 M -6.02 M -45.2 M - -79.7 M -24.4 M -23 M - - - -7.98 M - -4.76 M -5.8 M -5.28 M - -6.82 M -10.1 M -8.67 M - -6.39 M -10.2 M -8.79 M - -4.66 M -4.64 M -4.49 M - -2.4 M -2.43 M -2.98 M - -1.6 M -2.4 M -1.25 M - -1.97 M -2.25 M -4.24 M - -3.12 M -3.01 M -2.41 M - -1.3 M -1.29 M -677 K - -961 K - - - - - - - - - -

Operating Expenses

63.3 M 43.9 M 39.2 M 45.7 M - 80.2 M 24.9 M 23.5 M - 10.4 M 8.62 M 8.47 M - 6.24 M 6.78 M 5.77 M - 8.29 M 11.1 M 9.16 M - 7.86 M 11.2 M 9.28 M - 6.13 M 5.62 M 4.98 M - 3.88 M 3.41 M 3.48 M - 2.63 M 2.97 M 1.37 M - 1.97 M 2.25 M 4.25 M - 3.37 M 3.12 M 2.43 M - 1.32 M 1.31 M 684 K - 993 K - - - - - - - - - -

General and Administrative Expenses

50.4 M 33.8 M 28.2 M 29.3 M - 49.2 M 10.9 M 8.47 M - 3.32 M 3.17 M 2.85 M - 2.33 M 2.47 M 2.64 M - 2.77 M 2.46 M 2.98 M - 2.26 M 2.25 M 2 M - 1.62 M 1.7 M 2.01 M - 1.56 M 1.77 M 1.87 M - 1.68 M 2.2 M 1.02 M - 1.26 M 1.42 M 1.94 M - 1.71 M 1.43 M 1.29 M - 522 K 746 K 312 K - 248 K - - - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Soleno Therapeutics SLNO
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Soleno Therapeutics plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Diagnostics research industry

Issuer Price % 24h Market Cap Country
CareDx, Inc CareDx, Inc
CDNA
$ 54.31 0.32 % $ 2.89 B usaUSA
Celcuity Celcuity
CELC
$ 79.99 0.12 % $ 3.74 B usaUSA
Co-Diagnostics Co-Diagnostics
CODX
$ 1.1 1.85 % $ 1.46 M usaUSA
Castle Biosciences Castle Biosciences
CSTL
$ 34.88 0.09 % $ 1.01 B usaUSA
Danaher Corporation Danaher Corporation
DHR
$ 221.56 0.21 % $ 158 B usaUSA
DexCom DexCom
DXCM
$ 87.73 0.21 % $ 34.2 B usaUSA
Fulgent Genetics Fulgent Genetics
FLGT
$ 21.27 0.51 % $ 655 M usaUSA
Guardant Health Guardant Health
GH
$ 176.31 0.27 % $ 22.1 B usaUSA
Heska Corporation Heska Corporation
HSKA
- - $ 1.31 B usaUSA
HTG Molecular Diagnostics HTG Molecular Diagnostics
HTGM
- -20.0 % $ 1.06 M usaUSA
ICON Public Limited Company ICON Public Limited Company
ICLR
$ 163.9 0.2 % $ 12.9 B irlandaIrlanda
IDEXX Laboratories IDEXX Laboratories
IDXX
$ 522.02 0.1 % $ 42 B usaUSA
IQVIA Holdings IQVIA Holdings
IQV
$ 267.86 0.41 % $ 46 B usaUSA
Anixa Biosciences Anixa Biosciences
ANIX
$ 2.75 3.33 % $ 89.2 K usaUSA
Laboratory Corporation of America Holdings Laboratory Corporation of America Holdings
LH
$ 303.98 0.09 % $ 25.3 B usaUSA
Lantheus Holdings Lantheus Holdings
LNTH
$ 99.97 0.01 % $ 6.75 B usaUSA
Medpace Holdings Medpace Holdings
MEDP
$ 617.15 0.23 % $ 17.8 B usaUSA
Mettler-Toledo International Mettler-Toledo International
MTD
$ 1 492.34 0.11 % $ 30.8 B schweizSchweiz
Myriad Genetics Myriad Genetics
MYGN
$ 4.01 0.62 % $ 371 M usaUSA
ENDRA Life Sciences ENDRA Life Sciences
NDRA
$ 6.5 4.33 % $ 5.12 M usaUSA
NeoGenomics NeoGenomics
NEO
$ 18.36 0.03 % $ 2.35 B usaUSA
Neogen Corporation Neogen Corporation
NEOG
$ 13.57 2.72 % $ 2.95 B usaUSA
Natera Natera
NTRA
$ 390.79 0.41 % $ 53.4 B usaUSA
Biomerica Biomerica
BMRA
$ 2.61 0.36 % $ 7.61 M usaUSA
OPKO Health OPKO Health
OPK
$ 1.7 0.29 % $ 1.28 B usaUSA
RadNet RadNet
RDNT
$ 73.21 0.11 % $ 5.5 B usaUSA
Sotera Health Company Sotera Health Company
SHC
$ 18.29 0.45 % $ 5.19 B usaUSA
Neuronetics Neuronetics
STIM
$ 2.88 0.21 % $ 190 M usaUSA
Trinity Biotech plc Trinity Biotech plc
TRIB
$ 7.01 0.68 % $ 2.52 B irlandaIrlanda
Twist Bioscience Corporation Twist Bioscience Corporation
TWST
$ 158.47 0.93 % $ 9.48 B usaUSA
Biodesix Biodesix
BDSX
$ 29.29 4.05 % $ 221 M usaUSA
VolitionRx Limited VolitionRx Limited
VNRX
$ 0.25 2.99 % $ 31.4 M singaporeSingapore
Waters Corporation Waters Corporation
WAT
$ 420.57 0.52 % $ 25 B usaUSA
Exagen Exagen
XGN
$ 8.55 1.39 % $ 184 M usaUSA
Syneos Health Syneos Health
SYNH
- - $ 4.46 B usaUSA
Motus GI Holdings Motus GI Holdings
MOTS
- -34.28 % $ 263 K israelIsrael
Renalytix AI plc Renalytix AI plc
RNLX
- 5.66 % $ 22.7 M britainBritain
Chembio Diagnostics Chembio Diagnostics
CEMI
- 0.22 % $ 16.8 M usaUSA
Psychemedics Corporation Psychemedics Corporation
PMD
- -1.84 % $ 15.3 M usaUSA
Quotient Limited Quotient Limited
QTNT
- -11.32 % $ 1.1 M schweizSchweiz
T2 Biosystems T2 Biosystems
TTOO
- -39.35 % $ 313 K usaUSA
DermTech DermTech
DMTK
- -11.32 % $ 2.94 M usaUSA
Meridian Bioscience Meridian Bioscience
VIVO
- - $ 1.49 B usaUSA
Akumin Akumin
AKU
- -17.87 % $ 25.9 M canadaCanada
Accelerate Diagnostics Accelerate Diagnostics
AXDX
- -61.36 % $ 2.46 M usaUSA
Biocept Biocept
BIOC
- -13.05 % $ 7.29 M usaUSA
BioNano Genomics BioNano Genomics
BNGO
$ 1.7 0.55 % $ 9.26 M usaUSA
Burning Rock Biotech Limited Burning Rock Biotech Limited
BNR
$ 15.08 11.68 % $ 162 M chinaChina
Bioventus Bioventus
BVS
$ 13.61 2.55 % $ 907 M usaUSA
Brainsway Ltd. Brainsway Ltd.
BWAY
$ 13.45 0.88 % $ 457 M israelIsrael